Michael Marks, founding partner of WRVI Capital, has joined Atonarp's Board of Directors, and Shaun Holt, former CFO of Berkeley Lights, has been named Chief Operating Officer of Atonarp.

TOKYO - May 18, 2021 - Atonarp, a leading manufacturer of molecular sensing and diagnostic products for the healthcare, pharmaceutical and semiconductor industries, today announced that it has raised $50 million in Series D financing led by WRVI Capital Atonarp announced today that it has raised $50 million in Series D financing led by WRVI Capital. The new financing will allow the company to expand its operations to meet increasing customer demand in its current markets and accelerate the development and commercialization of its molecular diagnostic products. The company also announced the appointment of Sean Holt as Chief Operating Officer.

Nicholas Brathwaite, founding partner of WRVI Capital and Chairman of the Board of Atonarp, said, "Atonarp is paving the way for the future of point-of-care molecular diagnostic testing. As one of Atonarp's first investors, we recognized early on that the company's breakthrough molecular sensor technology would revolutionize the industry, and Atonarp, along with its experienced team of engineers, will expand its first-in-class, proven, transformative molecular sensor technology platform into new industries. Atonarp will expand its first-in-class, proven, transformative molecular sensor technology platform to new industries.

As lead investor, Michael Marks, founding partner of WRVI Capital, will join Atonarp's board of directors, and Nicholas Brathwaite will remain involved as board chairman. Also participating in the Series D are Furukawa Electric, Japan Post, Boscolo Intervest, ATI Korea, and Banner Industries; Atonarp has raised $111 million to date.

Yoshio Masutani, Vice President of Furukawa Electric, said, "Atnarup's goals are the same as ours, and we are very pleased to be working with them to help people make positive health decisions through their non-invasive testing platform. We are also very pleased to be able to support people in making positive health decisions through Atnarp's non-invasive testing platform.

New platform technology for lab-level results without the use of chemicals

Atonarp is a pioneer in the digitization of molecular diagnostics in the pharmaceutical, semiconductor manufacturing, industrial process control, and now life sciences sectors. The company uses proprietary spectroscopic technologies to detect, analyze, and quantify molecular information, and Atonarp offers a suite of molecular diagnostic products, including ATON-360™, an end-to-end platform that uses optical sensors to enable lab-quality results. Unlike traditional diagnostic and blood testing methods that rely on chemistry and require large amounts of biological samples for processing, Atonarp uses proprietary laser-based sensing and profiling technology to analyze small amounts of samples without any chemistry or expensive reagents to create digital molecular snapshots The system is capable of creating

Dr. Phyllis Gardner, Professor at Stanford University, said, "Point-of-care-testing is the future of medical diagnostics, but the industry has been hampered by expensive chemical-driven panels that require large volumes of samples and central laboratories for processing. Atnerp's molecular sensors scan and store entire digital datasets from very small sample volumes. This technology can support decentralized point-of-care diagnostics, which is essential for predictive and proactive healthcare practices, which in turn will improve patient diagnosis, treatment, and outcomes."

We have developed the industry's smallest, best-of-breed, cloud-connected, plug-and-play molecular diagnostics platform for real-time, quantitative, and unprecedentedly detailed analysis of chemical processes, and our disruptive We are poised to broadly deploy our disruptive platform across multiple industries and market segments. We are grateful to WRVI Capital and our other investors for their confidence in our vision and our approach to revolutionizing the way molecular data analysis is utilized." We are pleased to welcome Sean Holt as COO to support our next phase of growth as we expand our product offerings for industrial and life science applications."

Currently available molecular sensing platforms, Aston™ for semiconductor and process monitoring and LyoSentinel™ for pharmaceuticals, have transformed the way customers manage and optimize process control. In the life sciences, ATON-360 will transform the dialysis patient experience, the cell-based product discovery and development process, and in vitro diagnostics. Today, the company's digital molecular technology provides a rapid, painless, and cost-effective in vitro diagnostic solution that eliminates the need for phlebotomists while producing quantitative reports and analysis in seconds. The company's product development roadmap is also set to open new frontiers in hematology diagnostics with the development of in vivo diagnostic platforms. Atonalp is developing the world's first non-contact optical diagnostic platform capable of quantifying analytes in biofluids, which it plans to release in 2022. The company's ultimate vision in molecular diagnostics is to move from minimally invasive to non-invasive blood testing by optically probing blood vessels directly through the skin using laser-based sensing and profiling technology.

Veteran Life Sciences Leader Named COO

Sean Holt joins Atonarp as COO and will focus on driving operational excellence in Atonarp's global operations. prior to joining Atonarp, Sean was Chief Financial Officer at Berkeley Lights, Inc. where he led the digital cell biology company leading the company to a $205 million initial public offering. He has more than 20 years of experience leading finance, accounting, operations, manufacturing, supply chain, product development processes, and customer success functions for a variety of technology and life sciences companies ranging from startups to large corporations.

About Atonarp

Atonarp is a molecular diagnostics company reimagining the way sensing and diagnostic devices are applied to healthcare and industrial semiconductor processes to generate real-time, actionable data and achieve dramatically superior results. Founded in 2010, the company has operations in Japan, India, and the United States. For more information, please visit https://atonarp.com.

For press inquiries, please contact

JZ Rigney

jz@kingstonmarketing.group

‍